NCT04781686

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer: HCCSC G05 Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Zhou Fuxiang · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib plus Camrelizumab combined with docetaxel and S-1 as the first-line treatment of metastatic adenocarcinoma of gastric and gastroesophageal junction.

Conditions

• Metastatic Gastric Adenocarcinoma
• Metastatic Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab (200mg) will be given i.v. on day 1 of each 3-week cycle
DRUG	Apatinib Mesylate	Apatinib (250mg) will be administered orally once a day .
DRUG	S1	S1 (BSA\<1.25 40mg, BSA \>=1.25-\<1.5 50mg, BSA \>=1.5 60mg) will be administered orally twice daily on days 1-7 of each 3-week cycle
DRUG	Docetaxel injection	Docetaxel (75mg/m2 IV.drop) will be administered on day 1 of each 3-week cycle, for six cycles.

Timeline

• Start date: 2021-05-14
• Primary completion: 2024-08-01
• Completion: 2025-08-01
• First posted: 2021-03-04
• Last updated: 2021-05-17

Locations

1 site across 1 country: China